Zafgen (NASDAQ:ZFGN) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04, Fidelity Earnings reports.
Shares of ZFGN traded down $0.11 during mid-day trading on Friday, hitting $11.38. 241,175 shares of the company were exchanged, compared to its average volume of 150,715. Zafgen has a 1-year low of $3.41 and a 1-year high of $12.35. The company has a quick ratio of 8.42, a current ratio of 8.42 and a debt-to-equity ratio of 0.36. The company has a market cap of $373.57 million, a PE ratio of -5.99 and a beta of -0.23.
A number of brokerages have weighed in on ZFGN. BidaskClub upgraded shares of Zafgen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 27th. ValuEngine upgraded shares of Zafgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Wedbush began coverage on shares of Zafgen in a research report on Thursday, August 2nd. They issued an “outperform” rating and a $14.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $15.25.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ZFGN. Voya Investment Management LLC acquired a new position in shares of Zafgen during the 2nd quarter worth about $104,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Zafgen during the 2nd quarter worth about $110,000. Trexquant Investment LP acquired a new position in shares of Zafgen during the 2nd quarter worth about $117,000. Private Advisor Group LLC acquired a new position in shares of Zafgen during the 2nd quarter worth about $153,000. Finally, Barclays PLC raised its position in shares of Zafgen by 139,086.7% during the 1st quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 20,863 shares during the last quarter. Hedge funds and other institutional investors own 72.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/10/zafgen-zfgn-releases-earnings-results.html.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.